Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Annexon Biosciences

< Previous 1 2 Next >
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Biosciences to Present at the Jefferies London Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.